By Michael P. Savage(Editor), David L., M.d. Fischman(Editor)
Size : 6.38 MB
This book examines virtually all aspects of P2Y12 inhibitors – pharmacology, clinical uses, randomized trial results, guideline recommendations, and adverse drug effects. Important fundamental issues are reviewed including comparative pharmacology of P2Y12 inhibitors, randomized trials of clopidogrel in patients with coronary artery disease, DAPT duration after PCI, and role of platelet function testing. The newer P2Y12 inhibitors (prasugrel, ticagrelor, and cangrelor) receive special focus. Use of antiplatelet therapy in specific patient populations is discussed including patients with coronary bypass graft surgery, peripheral vascular disease, cerebrovascular disease, and structural heart disease. Management of antiplatelet therapy in patients who require anticoagulation is a particularly challenging clinical setting and is the topic of a featured review. Finally, adverse drug effects and reactions are examined in a section highlighting clopidogrel resistance, clopidogrel hypersensitivity, and bleeding complications.
Series: Cardiology Research and Clinical Developments
Hardcover: 308 pages
Publisher: Nova Science Pub Inc (March 19, 2019)
Dear All users
We have opened donation via amazon e-gift card.
for more information please check "Buy Points" page